Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hutmacher

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|December 2, 2005
Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonistMatthew M Hutmacher, Debu Mukherjee, Kenneth G Kowalski, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2008
Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasisR Conrad, F Geiser, G Haidl, et al.
Clinical Pharmacology and Therapeutics|November 26, 2010
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapineS Chapel, M M Hutmacher, H Bockbrader, et al.
The AAPS Journal|January 29, 2013
Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolitesMark Stroh, Matthew M Hutmacher, Jianmei Pang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 25, 2012
Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary diseaseJace C Nielsen, Matthew M Hutmacher, Adriaan Cleton, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2015
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patientsNeeraj Gupta, Yeamin Huh, Matthew M Hutmacher, et al.
Journal of Clinical Pharmacology|January 18, 2008
Performance characteristics for some typical QT study designs under the ICH E-14 guidanceMatthew M Hutmacher, Sunny Chapel, Marilyn A Agin, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 21, 2016
Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced ConstipationN Al-Huniti, J C Nielsen, M M Hutmacher, et al.
Journal of Clinical Pharmacology|September 1, 2011
Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritisSriram Krishnaswami, Matt M Hutmacher, Jeffery L Robbins, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Pharmacokinetics and Pharmacodynamics|December 2, 2005
Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonistMatthew M Hutmacher, Debu Mukherjee, Kenneth G Kowalski, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2008
Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasisR Conrad, F Geiser, G Haidl, et al.
Clinical Pharmacology and Therapeutics|November 26, 2010
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapineS Chapel, M M Hutmacher, H Bockbrader, et al.
The AAPS Journal|January 29, 2013
Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolitesMark Stroh, Matthew M Hutmacher, Jianmei Pang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 25, 2012
Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary diseaseJace C Nielsen, Matthew M Hutmacher, Adriaan Cleton, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2015
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patientsNeeraj Gupta, Yeamin Huh, Matthew M Hutmacher, et al.
Journal of Clinical Pharmacology|January 18, 2008
Performance characteristics for some typical QT study designs under the ICH E-14 guidanceMatthew M Hutmacher, Sunny Chapel, Marilyn A Agin, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 21, 2016
Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced ConstipationN Al-Huniti, J C Nielsen, M M Hutmacher, et al.
Journal of Clinical Pharmacology|September 1, 2011
Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritisSriram Krishnaswami, Matt M Hutmacher, Jeffery L Robbins, et al.
Pageof 4